Prime Therapeutics hailed as a Yellow Ribbon company

Designation signifies Prime's commitment to honoring and supporting active-duty military, veterans and their families

November 10, 2021
Large Banner with Blue Background and Yellow Ribbon on Top

The Minnesota Department of Military Affairs’ Beyond the Yellow Ribbon program named Prime Therapeutics (Prime) a Yellow Ribbon company for its support of Servicemembers and military families.

Prime’s work with the Yellow Ribbon program to develop a tailored action plan – demonstrating outward support for military employees and their families – culminated in the certification.

This year, Prime launched the Veterans, Families and Allies Network (VetFAN) employee resource group (ERG), a workplace group for military-affiliated employees and their supporters. One of the many changes Prime’s Beyond the Yellow Ribbon steering committee helped implement is an improved military leave policy, which provides 10 days of pay (in a rolling 12-month period) during an approved military leave.

“The Yellow Ribbon certification means Prime will join other companies and communities striving to serve our military families in a variety of ways,” said Dave Sagisser, manager, information technology and VetFAN co-chair for Prime. “Prime will become a ‘boots on the ground company’ that makes a difference for these families.”

“Officially being recognized as a Yellow Ribbon company is extremely important to Prime, its employees and its clients. It speaks to the commitment Prime has made to support our military and our country,” adds Marcus Caruso, director, shared services and Beyond the Yellow Ribbon steering committee member for Prime. “It signifies that Prime recognizes its employees who are either current or former military members, along with their families, are critical to the success of the organization.”

In 2022, Minnesota Governor Tim Walz will present Prime with the Yellow Ribbon certification in an official proclamation ceremony.

Read more about Prime’s support of employees serving in the military.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion